Parenteral Drug Association®

Connecting People, Science and Regulation®

Thursday, 21 May 2026			
9:00	Welcome and Introduction	Falk Klar, PDA Europe	
9:05	Welcome from the Co-Chairs	Margaret Bandel, Johnson & Johnson Paul Greenhalgh, Team Consulting	
Opening Session			
	Title to be announced	Sanofi	
	Title to be announced	Kymanox	
	Title to be announced	Regulatory Speaker invited	
	Q&A, Discussion		
11:15	Coffee Break, Poster Session & Exhibition		



Parenteral Drug Association®

Connecting People, Science and Regulation®

Session 1: Sus	tainability	
	How to Implement «Sustainability» in a Changing Environment	Novartis
	Applying Behavioral Science to Explore Perceptions of and Engagement with Sustainable Self-Injection Devices	Team Consulting
	Breaking the Triangle: Cost, Sustainability, and Scalability in Autoinjector Innovation	Eco-Inject
	Q&A, Discussion	
	LIVE Guided Poster Walk Engage with our Poster Presenters in our Exhibition Hall	
13:50	Lunch Break, Poster Session & Exhibition	
	Interactive Roundtable Session	
15:50	Networking Coffee Break, Poster Session & Exhibition	
Session 2: Inje	ession 2: Injection Devices	
	Title to be announced	Eli Lilly & Company
	IV versus SC - A Battleground with Conflicting Incentives	Trinity Life Science
	Title to be announced	Speaker invited
	Q&A, Discussion	
17:50	End of Conference Day 1 & Networking Event	





Connecting People, Science and Regulation®

Wednesday, 20 May 2026			
Speed Session 3: Large Volumes & Optimal Biological Dose			
	Addressing the Subcutaneous High-Dose Challenge	Novartis	
	Assessment of 10mL In vivo Injections with and without Hyaluronidase — A BD and Alteogen Collaboration	BD & Alteogen	
	Title to be announced	Speaker invited	
	Title to be announced	Speaker invited	
	Q&A, Discussion		
10:10	Coffee Break, Poster Session & Exhibition		
Session 4: Digi	tal Challenges		
	Smart Sensing for Better Therapies: How Connected Devices Transform Side Effect Management	Bayoomed	
	From Protocol Design to Patient Delivery: Implementing Digital Health Technology in Global Phase III Trials	Roche	
	Title to be announced	Speaker invited	
	Q&A, Discussion		
11:55	Lunch Break, Poster Session & Exhibition		





Connecting People, Science and Regulation®

Session 5: Platf	form and Device Strategy	
	Life Cycle of Drug-Device Combinations	Boehringer Ingelheim
	Title to be announced	Speaker invited
	When Platforms Evolve: Managing Connected Device Change in a Platformed World	Kymanox
	Q&A, Discussion	
14:10	Coffee Break, Poster Session & Exhibition	
	Passport Raffle via PDA Europe	
	Best Poster Presentation	
Closing Session		
	Patient-Centric Digital Education for Autoinjectors: A Case Study from Concept to Deployment	Team Consulting & Novartis
	Usability Challenges of Lyophilized Drug Products	Akiro/NovoNordisk
	Title to be announced - A Patient Perspective	Charles River
	Q&A, Discussion	





Connecting People, Science and Regulation®

PDA Miniverse: Medical Devices, Combination Products and Connected Health Conference 2026

Dublin, Ireland

21-22 May 2026

Agenda Preview

	Co-Chairs Conference Summary	Margaret Bandel, Johnson & Johnson Paul Greenhalgh, Team Consulting
	Closing Remarks & Farewell	Falk Klar, PDA Europe
16:25	End of Conference	

Agenda is subject to change without further notice

